4月1日 -
** 马克西姆集团将药物开发商Acrivon Therapeutics ACRV.O的PT值从24美元下调至7美元
** 理由是取消了卵巢癌和膀胱癌项目的优先权
** 经纪公司称："管理层宣布，由于卵巢癌的治疗门槛较高，而招募膀胱癌OncoSignature阳性患者存在困难，公司将取消这些项目的优先权。
** 补充说，子宫内膜癌的数据仍然相当强劲，安全性良好
** 新的目标价比上次收盘价高出 245
** 10家券商中有9家将该股评级为 "买入 "或更高，1家为 "持有"；PT中值为15美元--数据由LSEG编制
** 截至上次收盘，ACRV股价年累计下跌约66%；2024年上涨约22
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.